Milestone Scientific (MLSS) 10-Q 15 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 15, 2018
Document Information [Line Items]
Entity Registrant Name	MILESTONE SCIENTIFIC INC.
Entity Central Index Key	855,683
Trading Symbol	mlss
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		33,468,197
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 2,094,238	$ 2,636,956
Accounts receivable, net	833,836	1,535,513
Accounts receivable from related party	1,725,450	1,725,450
Notes receivable from financing transaction, current	500,000	500,000
Prepaid expenses and other current assets	494,717	436,410
Deferred cost related party	1,109,671	1,109,671
Inventories, net	3,265,058	3,379,209
Advances on contracts	984,408	697,192
Total current assets	11,007,378	12,020,401
Furniture, fixtures & equipment, net	115,502	141,760
Patents, net	2,552,382	2,789,748
Notes receivable from financing transaction, noncurrent	650,000	650,000
Other assets	26,878	26,878
Total assets	14,352,140	15,628,787
Current Liabilities:
Accounts payable	1,556,689	977,623
Accounts payable related party	1,075,078	985,678
Accrued expenses and other payables	1,928,654	2,287,908
Deferred profit, related party	714,717	751,500
Deferred revenue, related party	1,725,450	1,725,450
Total current liabilities	7,000,588	6,728,159
Deferred gain from financing transaction	1,400,000	1,400,000
Total liabilities	8,400,588	8,128,159
Commitments and Contingencies
Stockholders’ Equity
Series A convertible preferred stock, par value $.001, authorized 5,000,000 shares, and 7,000 shares issued and outstanding as of March 31, 2018 and December 31, 2017	7	7
Common stock, par value $.001; authorized 50,000,000 shares; 33,216,571 shares issued, 1,699,323 shares to be issued and 33,183,238 shares outstanding as of March 31, 2018; 33,191,571 shares issued, 1,401,247 shares to be issued and 33,158,238 shares outstanding as of December 31, 2017;	34,915	34,593
Additional paid-in capital	87,115,071	86,689,084
Accumulated deficit	(80,442,262)	(78,568,284)
Treasury stock, at cost, 33,333 shares	(911,516)	(911,516)
Total Milestone Scientific Inc. stockholders' equity	5,796,215	7,243,884
Noncontrolling interest	155,337	256,744
Total stockholders’ equity	5,951,552	7,500,628
Total liabilities and stockholders’ equity	$ 14,352,140	$ 15,628,787

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	7,000	7,000
Preferred stock, shares outstanding (in shares)	7,000	7,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	33,216,571	33,191,571
Common stock, shares to be issued (in shares)	1,699,323	1,401,247
Common stock, shares outstanding (in shares)	33,183,238	33,158,238
Treasury stock, at cost, shares (in shares)	33,333	33,333

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue
Product sales, net	$ 1,805,605	$ 3,688,988
Cost of products sold	562,676	1,402,285
Gross profit	1,242,929	2,286,703
Selling, general and administrative expenses	3,018,780	2,707,620
Research and development expenses	225,817	105,015
Total operating expenses	3,244,597	2,812,635
Loss from operations	(2,001,668)	(525,932)
Other expenses	(1,700)	(1,209)
Interest income	2,664	758
Loss before provision for income taxes and equity in net losses of equity investments	(2,000,704)	(526,383)
Provision for income taxes	(11,464)	(7,201)
Loss before equity in net losses of equity investments	(2,012,168)	(533,584)
Loss on earnings from China Joint Venture	36,783
Net loss	(1,975,385)	(577,985)
Net loss attributable to noncontrolling interests	(101,407)	(73,117)
Net loss attributable to Milestone Scientific Inc.	$ (1,873,978)	$ (504,868)
Net loss per share applicable to common stockholders—
Basic (in dollars per share)	$ (0.06)	$ (0.02)
Diluted (in dollars per share)	$ (0.06)	$ (0.02)
Weighted average shares outstanding and to be issued—
Basic (in shares)	34,766,014	32,004,548
Diluted (in shares)	34,766,014	32,004,548

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017	7,000	34,592,818
Balance at Dec. 31, 2017	$ 7	$ 34,593	$ 86,689,084	$ (78,568,284)	$ 256,744	$ (911,516)	$ 7,500,628
Stock based compensation			86,809				86,809
Common stock to be issued to employee for bonuses (in shares)		323,076
Common stock to be issued to employee for bonuses		$ 323	339,177				339,500
Net loss				(1,873,978)	(101,407)		(1,975,385)
Balance (in shares) at Mar. 31, 2018	7,000	34,915,894
Balance at Mar. 31, 2018	$ 7	$ 34,915	$ 87,115,071	$ (80,442,262)	$ 155,337	$ (911,516)	$ 5,951,552

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (1,975,385)	$ (577,985)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	27,625	16,860
Amortization of patents	237,366	17,682
Stock compensation	86,809	116,718
Equity income on China joint venture	(36,783)
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable	701,677	(824,182)
Decrease in accounts receivable related party		1,400,801
Decrease in inventories	114,151	68,885
Increase to in advances on contracts	(287,216)	(161,114)
Increase in prepaid expenses and other current assets	(58,307)	(207,613)
Increase in other assets		(9,523)
Decrease in deferred cost, related party		438,925
Increase (decrease) in accounts payable	579,070	(452,157)
Increase (decrease) in accounts payable related party	89,400	(152,748)
(Decrease) increase in accrued expenses and other payables	(19,757)	96,841
(Decrease) in deferred revenue, related party		(645,400)
Net cash used in operating activities	(541,350)	(874,010)
Cash flows from investing activities:
Purchase of property and equipment	(1,368)
Net cash used in investing activities	(1,368)
Cash flows from financing activities:
Net proceeds on Public offering		150,836
Proceeds from exercise of stock options		62,500
Net cash provided by financing activities		213,336
Net decrease in cash and cash equivalents	(542,718)	(660,674)
Cash and cash equivalents at beginning of period	2,636,956	3,602,229
Cash and cash equivalents at end of period	2,094,238	2,941,555
Supplemental disclosure of cash flow information:
Shares issued to employees for bonuses	339,500	195,000
Shares issued to consultants in lieu of cash payments		$ 43,750

Note 1 - Organization and Busin

Note 1 - Organization and Business	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 All references in this report to “Milestone Scientific,” “us,” “our,” “we,” the “Company” or “Milestone” refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Advanced Cosmetic Devices, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C ompuDent®; CompuMed®; CompuFlo®; DPS Dynamic Pressure Sensing technology®; Milestone Scientific ®; the Milestone logo ®; SafetyWand®; STA Single Tooth Anesthesia Device®; and The Wand ®. Milestone Scientific was incorporated in the State of Delaware in August 1989. The Wand® CompuDent®, STA Single Tooth Anesthesia Device® CompuMed®. CompuDent® CompuMed® 53 no During 2016, 510 CompuFlo CompuFlo June 2017, CompuFlo In December 2016, 510 not 510 510 2018.

Note 2 - Liquidity and Uncertai

Note 2 - Liquidity and Uncertainties	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2 In accordance with Accounting Standard Codification (“ASC”) 205 40, one December 2016 January 2017 one CompuFlo CompuFlo June 2017 CompuFlo Management believes that Milestone Scientific will have sufficient cash reserves to meet its anticipated obligations over the next twelve may The Company is subject to several risks like those of development stage companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital necessary to fund the development of its products, and competition from larger companies and other medical device companies that develop similar or substitute products. The Company's sales performance, selling and marketing expenditures to develop sales performance, as well as the status of each of its new product development programs and the resulting operating income (loss), will significantly impact its cash requirements.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 3 1. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned) and Milestone Medical (majority owned). Milestone Education is a variable interest entity of which Milestone Scientific is the primary beneficiary and is consolidated into Milestone Scientific's financial statements. All significant, intra-entity transactions and balances have been eliminated in the consolidation. 2. The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10Q 10 X. not not may December 31, 2017, 10 3. Certain reclassifications have been made to the 2017 2018 no 4. Under ASC 606, 606, five (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with third Revenue from product sales are recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are FOB destination, revenue is recognized upon delivery. The Company has no Sales Returns We generally do not not Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 Disaggregation of Revenue We operate in two 12 three March 31, 2018 5.Variable A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific’s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Milestone Scientific became the primary beneficiary of Milestone Education as of January 2017. Because Milestone Scientific had an increasing variable interest in Milestone China, it considered the guidance in ASC 810, not ● Power Criterion: The power to direct the activities that most significantly impact the entity’s economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE. Milestone management does not not 53% not 810. not 6. Milestone Scientific considers all highly liquid investments purchased with an original maturity of three 7. Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most of credit sales are due within 90 not March 31, 2018 December 31, 2017, $10,000. 8. Milestone Scientific values note receivable at historic cost less amount paid against principle. Milestone Scientific estimates losses on the note-based payments and credit quality of the debtor. 9. Milestone Scientific generally does not not 10. Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first March 31, 2018, December 31, 2017, $220,000. 11. Investments in which Milestone Scientific can exercise significant influence, but do not may 12. Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two seven 13. Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized at the estimated average useful life of the patent. These patents and developed technology are recorded at the acquisition cost. Patent defense costs, to the extent applicable, are expensed as incurred. Patent applications filed, and patents obtained in foreign countries are subject to the laws and procedures that differ from those in the United States. Patent protection in foreign countries may may not no 14. As of March 31, 2018, no no March 31, 2018 December 31, 2017. 15. Shipping and handling costs, if any, are paid by or billed to customers at the time of shipments. Domestic and international shipments are FOB warehouse; therefore, no 16. Research and development costs, which consist principally of new product development costs payable to third 17. Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. 18. Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, Since Milestone Scientific had net losses for 2018 2017, not 3,510,335 3,710,335 March 31, 2018 December 31, 2017, 19. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates . 20. Fair Value Measurements: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may 21. Milestone Scientific accounts for stock-based compensation under ASC 718, 718 The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model. In accordance with the provisions of ASC 505, three March 31, 2018 2017, $4,000 $17,100 22. In May 2014, No. 2014 09, 606 606 January 1, 2018 In connection with the adoption, we performed a review of our existing revenue arrangements as of January 1, 2018 five 606. Based on our analysis, there were no no In February 2016, No. 2016 02, 842 January 1, 2019. In August 2016, No. 2016 15, 230 March 31, 2018 no In May 2017, No. 2017 09, 718 March 31, 2018 no In February 2018, No. 2018 02, 220 not December 15, 2018 not

Note 4 - Notes Receivable

Note 4 - Notes Receivable	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 4 In June 2017, forty 40% 10 $1,400,000 $125,000 $1,275,000 $125,000 10 $1,400,000 first two 10 The transaction has been accounted for as a secured financing and Milestone Scientific will continue to account for its relationship with Milestone China under the equity method of accounting. A note receivable is presented on the Company’s condensed consolidated balance sheet, along with a deferral from financing transaction ( $1,400,000 forty 40% As of March 2, 2018, April 2018, $250,000 1.4 16

Note 5 - Inventories

Note 5 - Inventories	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 5 Inventories at March 31, 2018 December 31, 2017 March 31, 2018 December 31, 2017 Dental finished goods $ 2,786,334 $ 2,846,272 Medical finished goods, net 453,454 475,285 Component parts and other materials 25,270 57,652 Total $ 3,265,058 $ 3,379,209 As of March 31, 2018, December 31, 2017, $220,000 .

Note 6 - Advances on Contracts

Note 6 - Advances on Contracts	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Advances to Contract Manufacturer [Text Block]	NOTE 6 — ADVANCES ON CONTRACTS The advances on contracts represent funding of future STA inventory purchases and Epidural replacements parts. The balance of the advances as of March 31, 2018 December 31, 2017 $984,408 $697,192

Note 7 - Consolidation of Varia

Note 7 - Consolidation of Variable Interest Entity	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Variable Interest Entity Disclosure [Text Block]	NOTE 7 Milestone Education is a 50% 2013 March 31, 2018, 2017, 72% 82%

Note 8 - Investment in Unconsol

Note 8 - Investment in Unconsolidated Affiliate	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 8 Milestone China Ltd. In June 2014, $1 772 40% three March 31, 2018, 2017, $0 $44,401, March 31, 2018 December 31, 2017, $0. March 31, 2018, December 31, 2017, $3,524,617 $3,147,470, As of March 2, 2018, may $250,000 March 31, 2018, not not 4 Milestone Scientific had no three March 31, 2018. $1,001,800 three March 31, 2017. Due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to third 323, 40% not third March 31, 2018 December 31, 2017, $714,717 $751,500, The following table includes summarized financial information (unaudited) of Milestone China: March 31, 2018 December 31, 2017 Assets: Current assets $ 10,678,999 $ 13,127,422 Non-current assets 3,381,262 3,213,520 Total assets: $ 14,060,261 $ 16,340,942 Liabilities: Current liabilities 12,414,362 18,468,937 Stockholders' equity 1,645,899 (2,127,995 ) Total liabilities and stockholders’ equity $ 14,060,261 $ 16,340,942 March 31, 2018 March 31, 2017 Net sales $ 756,956 $ 427,400 Cost of goods sold (447,611 ) (479,411 ) Gross Profit 309,345 (52,011 ) Other Expenses (1,252,213 ) (958,055 ) Net Losses $ (942,868 ) $ (1,010,066 )

Note 9 - Patents

Note 9 - Patents	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	NOTE 9 Patents at March 31, 2018 December 31, 2017 2018 2017 Cost Accumulated Amortization Net Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (805,216 ) $ 572,647 $ 1,377,863 $ (787,821 ) $ 590,042 Epidural-Apad acquired patents 2,639,647 (659,912 ) 1,979,735 2,639,647 (439,941 ) 2,199,706 Total $ 4,017,510 $ (1,465,128 ) $ 2,552,382 $ 4,017,510 $ (1,227,762 ) $ 2,789,748 Patents are amortized utilizing the straight-line method over estimated useful lives ranging from 3 20 5 On July 13, 2017, 1,646,358 $2,486,000 not twenty-five 250,000 March 31, 2018, December 31, 2017, $295,000 $2,639,000, three Amortization expense was $237,366 $17,682 three March 31, 2018 2017, five March 31, 2018 $927,000, $920,000, $259,000, $39,000 $39,000,

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 10 Shares to be Issued As of March 31, 2018, December 31, 2017, 1,699,323 1,401,247 Shares Reserved for Future Issuance As of March 31, 2018, December 31, 2017 5,209,658 5,111,582 3,510,335, 3,710,335 March 31, 2018 December 31, 2017, 1,699,323 1,401,247

Note 11 - Income Taxes

Note 11 - Income Taxes	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 11 Due to Milestone Scientific's history of operating losses, a full valuation allowances have been provided for all of Milestone Scientific's deferred tax assets. As of March 31, 2018, December 31, 2017, no The utilization of Milestone Scientific's net operating losses may 382 may 100% Accounting for uncertainties in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. At March 31, 2018, December 31, 2017, no No 2014, 2015, 2016 2017

Note 12 - Segment and Geographi

Note 12 - Segment and Geographic Data	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Product Sales and Significant Customers and Vendors Disclosure [Text Block]	NOTE 12 We conduct our business through two Sales Three months ended March 31, Net Sales: 2018 2017 Dental $ 1,769,105 $ 3,688,988 Medical 36,500 - Total $ 1,805,605 $ 3,688,988 Operating (Loss): 2018 2017 Dental $ 357,165 $ 1,275,631 Medical (708,382 ) (624,326 ) Corporate (1,650,451 ) (1,177,237 ) Total $ (2,001,668 ) $ (525,932 ) Depreciation and Amortization: 2018 2017 Dental $ 4,141 $ 4,468 Medical 16,877 9,360 Corporate 243,973 20,714 Total $ 264,991 $ 34,542 Loss before taxes and equity in losses of affiliates: 2018 2017 Dental $ 359,822 $ 1,276,099 Medical (708,954 ) (624,796 ) Corporate (1,651,572 ) (1,177,686 ) Total $ (2,000,704 ) $ (526,383 ) Total Assets: March 31, 2018 December 31, 2017 Dental $ 9,302,960 $ 10,255,144 Medical 667,770 655,513 Corporate 4,381,4100 4,718,130 $ 14,352,140 $ 15,628,787 The following table presents information about our operations by geographic area as March 31, 2018 2017. Domestic-US & Canada March 31, 2018 March 31, 2017 Devices $ 121,048 $ 185,645 Handpieces 768,531 1,510,486 Other 28,851 18,941 Total Domestic US & Canada $ 918,430 $ 1,715,072 International ROW Devices $ 279,468 $ 358,670 Handpieces 582,827 583,349 Other 24,880 30,097 Total International-ROW $ 887,175 $ 972,116 International-China Devices $ - $ 1,000,000 Handpieces - - Other - 1,800 Total International $ - $ 1,001,800 Domestic. International Analysis Domestic-US & Canada $ 918,430 $ 1,715,072 International -ROW 887,175 972,116 International -China - 1,001,800 Total Product Sales $ 1,805,605 $ 3,688,988

Note 13 - Concentration

Note 13 - Concentration	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 13 Milestone Scientific has informal arrangements with a third CompuDent CompuMed January 2017, 2,000 4th 2017. March 31, 2018, $186,965. January 2018, 2,000 third 2018, $1,397,440. 984,408 $697,192 March 31, 2018 December 31, 2017, March 31, 2018 December 31, 2017. For the three March 31, 2018, 54% one three March 31, 2017, 79% two one 52%, 27%, $1,923,950, 76% March 31, 2018. $2,555,476, 78% December 31, 2017.

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 14 Milestone Scientific has a manufacturing agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were $351,280 $452,352 three March 31, 2018 2017, March 31, 2018, December 31, 2017, $1,075,078 $985,678 Milestone Scientific had no three March 31, 2018. $1,001,800 three March 31, 2017. In August 2016, three $50,000 three March 31, 2018 2017. In January 2017, 12 12 $20,000 three March 31, 2018 2017.

Note 15 - Commitments

Note 15 - Commitments	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 15 ( 1 Milestone Scientific has informal arrangements with a third January 2017, 2,000 4th 2017. March 31, 2018, $186,965. January 2018 2,000 3rd 2018, $1,397,440. 984,408 $697,192 March 31, 2018 December 31, 2017, ( 2 In February 2018, October 2, 2017, $175,000, $80,555 March 2018. nine March 2018. The technology underlying the Safety Wand® and CompuFlo CompuDent January 1, 2005. 2.5% 5% 8,333 third The Director of Clinical Affairs’ royalty fee was $85,769 $131,908 three March 31, 2018 2017, $68,751 three March 31, 2018 2017, In January 2017, 12 12 $20,000 three March 31, 2018 2017.

Note 16 - Subsequent Events

Note 16 - Subsequent Events	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 16 In April 2018, $250,000 1.4 $1,150,000 $1,400,000, no 4. In May 2018, twelve 500,000 $1.00; 1 st 400,000 30 60 500,000 1.00, 4 5 400,000 500,000

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	1. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned) and Milestone Medical (majority owned). Milestone Education is a variable interest entity of which Milestone Scientific is the primary beneficiary and is consolidated into Milestone Scientific's financial statements. All significant, intra-entity transactions and balances have been eliminated in the consolidation.
Basis of Accounting, Policy [Policy Text Block]	2. The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10Q 10 X. not not may December 31, 2017, 10
Reclassification, Policy [Policy Text Block]	3. Certain reclassifications have been made to the 2017 2018 no
Revenue Recognition, Policy [Policy Text Block]	4. Under ASC 606, 606, five (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with third Revenue from product sales are recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are FOB destination, revenue is recognized upon delivery. The Company has no Sales Returns We generally do not not Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 Disaggregation of Revenue We operate in two 12 three March 31, 2018
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	5.Variable A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific’s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Milestone Scientific became the primary beneficiary of Milestone Education as of January 2017. Because Milestone Scientific had an increasing variable interest in Milestone China, it considered the guidance in ASC 810, not ● Power Criterion: The power to direct the activities that most significantly impact the entity’s economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE. Milestone management does not not 53% not 810. not
Cash and Cash Equivalents, Policy [Policy Text Block]	6. Milestone Scientific considers all highly liquid investments purchased with an original maturity of three
Trade and Other Accounts Receivable, Policy [Policy Text Block]	7. Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most of credit sales are due within 90 not March 31, 2018 December 31, 2017, $10,000.
Finance, Loans and Leases Receivable, Policy [Policy Text Block]	8. Milestone Scientific values note receivable at historic cost less amount paid against principle. Milestone Scientific estimates losses on the note-based payments and credit quality of the debtor.
Standard Product Warranty, Policy [Policy Text Block]	9. Milestone Scientific generally does not not
Inventory, Policy [Policy Text Block]	10. Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first March 31, 2018, December 31, 2017, $220,000.
Equity Method Investments [Policy Text Block]	11. Investments in which Milestone Scientific can exercise significant influence, but do not may
Property, Plant and Equipment, Policy [Policy Text Block]	12. Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two seven
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	13. Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized at the estimated average useful life of the patent. These patents and developed technology are recorded at the acquisition cost. Patent defense costs, to the extent applicable, are expensed as incurred. Patent applications filed, and patents obtained in foreign countries are subject to the laws and procedures that differ from those in the United States. Patent protection in foreign countries may may not no
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	14. As of March 31, 2018, no no March 31, 2018 December 31, 2017.
Shipping and Handling Cost, Policy [Policy Text Block]	15. Shipping and handling costs, if any, are paid by or billed to customers at the time of shipments. Domestic and international shipments are FOB warehouse; therefore, no
Research and Development Expense, Policy [Policy Text Block]	16. Research and development costs, which consist principally of new product development costs payable to third
Income Tax, Policy [Policy Text Block]	17. Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
Earnings Per Share, Policy [Policy Text Block]	18. Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, Since Milestone Scientific had net losses for 2018 2017, not 3,510,335 3,710,335 March 31, 2018 December 31, 2017,
Use of Estimates, Policy [Policy Text Block]	19. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates .
Fair Value of Financial Instruments, Policy [Policy Text Block]	20. Fair Value Measurements: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	21. Milestone Scientific accounts for stock-based compensation under ASC 718, 718 The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model. In accordance with the provisions of ASC 505, three March 31, 2018 2017, $4,000 $17,100
New Accounting Pronouncements, Policy [Policy Text Block]	22. In May 2014, No. 2014 09, 606 606 January 1, 2018 In connection with the adoption, we performed a review of our existing revenue arrangements as of January 1, 2018 five 606. Based on our analysis, there were no no In February 2016, No. 2016 02, 842 January 1, 2019. In August 2016, No. 2016 15, 230 March 31, 2018 no In May 2017, No. 2017 09, 718 March 31, 2018 no In February 2018, No. 2018 02, 220 not December 15, 2018 not

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2018 December 31, 2017 Dental finished goods $ 2,786,334 $ 2,846,272 Medical finished goods, net 453,454 475,285 Component parts and other materials 25,270 57,652 Total $ 3,265,058 $ 3,379,209

Note 8 - Investment in Uncons25

Note 8 - Investment in Unconsolidated Affiliate (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Equity Method Investments [Table Text Block]	March 31, 2018 December 31, 2017 Assets: Current assets $ 10,678,999 $ 13,127,422 Non-current assets 3,381,262 3,213,520 Total assets: $ 14,060,261 $ 16,340,942 Liabilities: Current liabilities 12,414,362 18,468,937 Stockholders' equity 1,645,899 (2,127,995 ) Total liabilities and stockholders’ equity $ 14,060,261 $ 16,340,942 March 31, 2018 March 31, 2017 Net sales $ 756,956 $ 427,400 Cost of goods sold (447,611 ) (479,411 ) Gross Profit 309,345 (52,011 ) Other Expenses (1,252,213 ) (958,055 ) Net Losses $ (942,868 ) $ (1,010,066 )

Note 9 - Patents (Tables)

Note 9 - Patents (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2018 2017 Cost Accumulated Amortization Net Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (805,216 ) $ 572,647 $ 1,377,863 $ (787,821 ) $ 590,042 Epidural-Apad acquired patents 2,639,647 (659,912 ) 1,979,735 2,639,647 (439,941 ) 2,199,706 Total $ 4,017,510 $ (1,465,128 ) $ 2,552,382 $ 4,017,510 $ (1,227,762 ) $ 2,789,748

Note 12 - Segment and Geograp27

Note 12 - Segment and Geographic Data (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Sales Three months ended March 31, Net Sales: 2018 2017 Dental $ 1,769,105 $ 3,688,988 Medical 36,500 - Total $ 1,805,605 $ 3,688,988 Operating (Loss): 2018 2017 Dental $ 357,165 $ 1,275,631 Medical (708,382 ) (624,326 ) Corporate (1,650,451 ) (1,177,237 ) Total $ (2,001,668 ) $ (525,932 ) Depreciation and Amortization: 2018 2017 Dental $ 4,141 $ 4,468 Medical 16,877 9,360 Corporate 243,973 20,714 Total $ 264,991 $ 34,542 Loss before taxes and equity in losses of affiliates: 2018 2017 Dental $ 359,822 $ 1,276,099 Medical (708,954 ) (624,796 ) Corporate (1,651,572 ) (1,177,686 ) Total $ (2,000,704 ) $ (526,383 ) Total Assets: March 31, 2018 December 31, 2017 Dental $ 9,302,960 $ 10,255,144 Medical 667,770 655,513 Corporate 4,381,4100 4,718,130 $ 14,352,140 $ 15,628,787
Sales by Product and by Geographical Region [Table Text Block]	Domestic-US & Canada March 31, 2018 March 31, 2017 Devices $ 121,048 $ 185,645 Handpieces 768,531 1,510,486 Other 28,851 18,941 Total Domestic US & Canada $ 918,430 $ 1,715,072 International ROW Devices $ 279,468 $ 358,670 Handpieces 582,827 583,349 Other 24,880 30,097 Total International-ROW $ 887,175 $ 972,116 International-China Devices $ - $ 1,000,000 Handpieces - - Other - 1,800 Total International $ - $ 1,001,800 Domestic. International Analysis Domestic-US & Canada $ 918,430 $ 1,715,072 International -ROW 887,175 972,116 International -China - 1,001,800 Total Product Sales $ 1,805,605 $ 3,688,988

Note 1 - Organization and Bus28

Note 1 - Organization and Business (Details Textual)	3 Months Ended
	Mar. 31, 2018
Number of Countries in which Entity Operates	53
UNITED STATES
Number of Medical Instruments Sold	0

Note 3 - Summary of Significa29

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Number of Operating Segments	2
Allowance for Doubtful Accounts Receivable, Ending Balance	$ 10,000		$ 10,000
Inventory Valuation Reserves, Ending Balance	220,000		220,000
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance	13
Impairment of Long-Lived Assets Held-for-use	0		$ 0
Share-based Goods and Nonemployee Services Transaction, Capitalized Cost	$ 4,000
Income from Non-employee Options		$ 17,100
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,510,335		3,710,335
Minimum [Member]
Property, Plant and Equipment, Useful Life	2 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years
Milestone China [Member]
Variable Interest Entity Majority Shareholder Ownership Percentage	53.00%

Note 4 - Notes Receivable (Deta

Note 4 - Notes Receivable (Details Textual) - Milestone China [Member] - USD ($) shares in Millions	1 Months Ended
	Apr. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Dec. 31, 2017	May 31, 2017	Jun. 30, 2014
Equity Method Investment, Ownership Percentage						40.00%
Equity Method Investment, Deferred Gain on Sale		$ 1,400,000
Equity Method Investments		$ 0	$ 0	$ 0		$ 1,000,000
Sale of Variable Interest Entity's Shares [Member]
Equity Method Investment, Ownership Percentage					40.00%
Option to Repurchase, Period		10 years
Price for Shares of Variable Interest Entity Interest Sold		$ 1,400,000
Proceeds from Sale of Variable Interest Entity Shares with Agreement to Repurchase		125,000
Financing Receivable, Net, Total		1,275,000
Note Receivable, Quarterly Installment Amount		125,000
Option to Repurchase Variable Interest Entity Shares, Purchase Price		$ 1,400,000
Option to Repurchase Variable Entity Shares at Specified Purchase Price, Period		2 years
Sale of Variable Interest Entity's Shares [Member] | Subsequent Event [Member]
Return Obligation, Amount Repaid	$ 250,000
Termination Agreement, Number of Shares Returned	1.4

Note 5 - Inventories (Details T

Note 5 - Inventories (Details Textual) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Inventory Valuation Reserves, Ending Balance	$ 220,000	$ 220,000

Note 5 - Inventories - Summary

Note 5 - Inventories - Summary of Inventories (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Component parts and other materials	$ 25,270	$ 57,652
Inventories, net	3,265,058	3,379,209
Dental Segment [Member]
Finished goods	2,786,334	2,846,272
Medical Segment [Member]
Finished goods	$ 453,454	$ 475,285

Note 6 - Advances on Contracts

Note 6 - Advances on Contracts (Details Textual) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Advances on Inventory Purchases	$ 984,408	$ 697,192

Note 7 - Consolidation of Var34

Note 7 - Consolidation of Variable Interest Entity (Details Textual) - Milestone Education LLC [Member]	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	50.00%
Percentage of Revenue from Services Performed to Variable Interest Entity	72.00%	82.00%

Note 8 - Investment in Uncons35

Note 8 - Investment in Unconsolidated Affiliate (Details Textual)	1 Months Ended	3 Months Ended		12 Months Ended
	Jun. 30, 2014USD ($)	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)	Mar. 02, 2018USD ($)	Jun. 30, 2017USD ($)	May 31, 2017
Income (Loss) from Equity Method Investments, Total		$ 36,783
Revenue from Contract with Customer, Including Assessed Tax		1,805,605	3,688,988
Milestone China [Member]
Equity Method Investments	$ 1,000,000	0		$ 0		$ 0
Long-term Purchase Commitment, Minimum Quantity Required	772
Equity Method Investment, Ownership Percentage	40.00%
Income (Loss) from Equity Method Investments, Total		0	44,401
Cost-method Investments, Realized Losses		$ 3,524,617		$ 3,147,470
Equity Method Investment, Deferred Intercompany Profit (Loss), Percentage		40.00%
Milestone China [Member] | Accounts Receivable from Related Parties [Member]
Equity Method Investment, Deferred Intercompany Profit (Loss)		$ 751,500
Milestone China [Member] | Instruments and Handpieces [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 0	$ 1,001,800
Milestone China [Member] | Sale of Variable Interest Entity's Shares [Member]
Equity Method Investment, Ownership Percentage							40.00%
Milestone China [Member] | Sale of Variable Interest Entity's Shares [Member] | Upon Exercise of Default Agreement [Member]
Return Obligation, Amount					$ 250,000

Note 8 - Investment in Uncons36

Note 8 - Investment in Unconsolidated Subsidiaries - Summarized Financial Information (Unaudited) of Milestone China (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue from Contract with Customer, Including Assessed Tax	$ 1,805,605	$ 3,688,988
Cost of goods sold	(562,676)	(1,402,285)
Gross Profit	1,242,929	2,286,703
Net Losses	(1,975,385)	(577,985)
Milestone China [Member]
Current assets	10,678,999	13,127,422
Non-current assets	3,381,262	3,213,520
Total assets:	14,060,261	16,340,942
Current liabilities	12,414,362	18,468,937
Stockholders' equity	1,645,899	(2,127,995)
Total liabilities and stockholders’ equity	14,060,261	16,340,942
Revenue from Contract with Customer, Including Assessed Tax	756,956	427,400
Cost of goods sold	(447,611)	(479,411)
Gross Profit	309,345	(52,011)
Other Expenses	(1,252,213)	(958,055)
Net Losses	$ (942,868)	$ (1,010,066)

Note 9 - Patents (Details Textu

Note 9 - Patents (Details Textual)	Jul. 13, 2017USD ($)shares	Jul. 13, 2017EUR (€)shares	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)
Amortization of Intangible Assets, Total			$ 237,366	$ 17,682
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year			927,000
Finite-Lived Intangible Assets, Amortization Expense, Year Two			920,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three			259,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four			39,000
Finite-Lived Intangible Assets, Amortization Expense, Year Five			39,000
APAD Octrooi B.V. and APAD B.V. [Member]
Stock Issued During Period, Shares, Purchase of Assets | shares	1,646,358	1,646,358
Stock Issued During Period, Value, Purchase of Assets	$ 2,486,000
Asset Purchase Agreement, Post-closing Adjustments, Percentage of Initial Shares, Maximum	25.00%	25.00%
Asset Purchase Agreement, Post-closing Adjustments, Amount of Initial Shares, Maximum | €		€ 250,000
Asset Purchase Agreement, Post-closing Adjustments, Liabilities			$ 295,000		$ 295,000
Patents [Member]
Finite-Lived Intangible Asset, Useful Life	3 years	3 years
Finite-lived Intangible Assets Acquired	$ 2,639,000
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life			3 years
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life			20 years
Patents [Member] | Weighted Average [Member]
Finite-Lived Intangible Asset, Useful Life			5 years

Note 9 - Patents - Summary of P

Note 9 - Patents - Summary of Patents (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Patents, cost	$ 4,017,510	$ 4,017,510
Patents, accumulated amortization	(1,465,128)	(1,227,762)
Patents, net	2,552,382	2,789,748
Foundation Intellectual Property Patents [Member]
Patents, cost	1,377,863	1,377,863
Patents, accumulated amortization	(805,216)	(787,821)
Patents, net	572,647	590,042
Epidural-Apad Patents [Member]
Patents, cost	2,639,647	2,639,647
Patents, accumulated amortization	(659,912)	(439,941)
Patents, net	$ 1,979,735	$ 2,199,706

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Details Textual) - shares	Mar. 31, 2018	Dec. 31, 2017
Common Stock, Capital Shares Reserved for Future Issuance	5,209,658	5,111,582
Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance	1,699,323	1,401,247
Other Stock Options and Warrants [Member]
Common Stock, Capital Shares Reserved for Future Issuance	3,510,335	3,710,335
Chief Executive Officer, Chief Financial Officer and Employees [Member]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance	1,699,323	1,401,247

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards, Valuation Allowance, Total	$ 0	$ 0
Percentage of Valuation Allowance	100.00%
Unrecognized Tax Benefits, Ending Balance	$ 0	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total	$ 0	$ 0
Earliest Tax Year [Member]
Open Tax Year	2,014
Latest Tax Year [Member]
Open Tax Year	2,017

Note 12 - Segment and Geograp41

Note 12 - Segment and Geographic Data (Details Textual)	3 Months Ended
	Mar. 31, 2018
Number of Reportable Segments	2

Note 12 - Segment and Geograp42

Note 12 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Product sales, net	$ 1,805,605	$ 3,688,988
Operating Income (Loss)	(2,001,668)	(525,932)
Depreciation and Amortization	264,991	34,542
Income before taxes and equity in earnings of affiliates:	(2,000,704)	(526,383)
Total assets	14,352,140	15,628,787	$ 15,628,787
Corporate, Non-Segment [Member]
Operating Income (Loss)	(1,650,451)	(1,177,237)
Depreciation and Amortization	243,973	20,714
Income before taxes and equity in earnings of affiliates:	(1,651,572)	(1,177,686)
Total assets	43,814,100	4,718,130
Dental Segment [Member] | Operating Segments [Member]
Product sales, net	1,769,105	3,688,988
Operating Income (Loss)	357,165	1,275,631
Depreciation and Amortization	4,141	4,468
Income before taxes and equity in earnings of affiliates:	359,822	1,276,099
Total assets	9,302,960	10,255,144
Medical Segment [Member] | Operating Segments [Member]
Product sales, net	36,500
Operating Income (Loss)	(708,382)	(624,326)
Depreciation and Amortization	16,877	9,360
Income before taxes and equity in earnings of affiliates:	(708,954)	(624,796)
Total assets	$ 667,770	$ 655,513

Note 12 - Segment and Geograp43

Note 12 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Product sales, net	$ 1,805,605	$ 3,688,988
Product sales, net	1,805,605	3,688,988
Domestic [Member]
Product sales, net	918,430	1,715,072
Product sales, net	918,430	1,715,072
Domestic [Member] | Devices [Member]
Product sales, net	121,048	185,645
Product sales, net	121,048	185,645
Domestic [Member] | Handpieces [Member]
Product sales, net	768,531	1,510,486
Product sales, net	768,531	1,510,486
Domestic [Member] | Manufactured Product, Other [Member]
Product sales, net	28,851	18,941
Product sales, net	28,851	18,941
Rest of World [Member]
Product sales, net	887,175	972,116
Product sales, net	887,175	972,116
Rest of World [Member] | Devices [Member]
Product sales, net	279,468	358,670
Product sales, net	279,468	358,670
Rest of World [Member] | Handpieces [Member]
Product sales, net	582,827	583,349
Product sales, net	582,827	583,349
Rest of World [Member] | Manufactured Product, Other [Member]
Product sales, net	24,880	30,097
Product sales, net	24,880	30,097
CHINA
Product sales, net		1,001,800
Product sales, net		1,001,800
CHINA | Devices [Member]
Product sales, net		1,000,000
Product sales, net		1,000,000
CHINA | Handpieces [Member]
Product sales, net
Product sales, net
CHINA | Manufactured Product, Other [Member]
Product sales, net		1,800
Product sales, net		$ 1,800

Note 13 - Concentration (Detail

Note 13 - Concentration (Details Textual)	1 Months Ended		3 Months Ended		12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Mar. 31, 2018USD ($)	Mar. 31, 2017	Dec. 31, 2017USD ($)
Advances on Inventory Purchases			$ 984,408		$ 697,192
Accounts Receivable, Gross			$ 1,923,950		$ 2,555,476
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Number of Customers			1	2
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Concentration Risk, Percentage			54.00%
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Concentration Risk, Percentage				79.00%
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration Risk, Percentage				52.00%
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration Risk, Percentage				27.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage			76.00%		78.00%
Instruments [Member]
Purchase Commitment Number Of Units		2,000
Purchase Commitment, Remaining Minimum Amount Committed			$ 186,965
Devices [Member]
Purchase Commitment Number Of Units	2,000
Purchase Commitment, Remaining Minimum Amount Committed			$ 1,397,440

Note 14 - Related Party Trans45

Note 14 - Related Party Transactions (Details Textual) - USD ($)	1 Months Ended		3 Months Ended
	Jan. 31, 2017	Aug. 31, 2016	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Revenue from Contract with Customer, Including Assessed Tax			$ 1,805,605	$ 3,688,988
Milestone China [Member] | Handpieces and Devices [Member]
Revenue from Contract with Customer, Including Assessed Tax			0	1,001,800
Manufacturing Agreement for Handpieces [Member]
Related Party Transaction, Purchases from Related Party			351,280	452,352
Due to Related Parties, Total			1,075,078		$ 985,678
Consulting Services [Member]
Consulting Services Agreement, Term		3 years
Related Party Transaction, Expenses from Transactions with Related Party			50,000	50,000
Consulting Services [Member] | Innovest S.p.A. [Member]
Consulting Services Agreement, Term	1 year
Related Party Transaction, Expenses from Transactions with Related Party			$ 20,000	$ 20,000

Note 15 - Commitments (Details

Note 15 - Commitments (Details Textual)	Jan. 01, 2005shares	Mar. 31, 2018USD ($)	Feb. 28, 2018USD ($)	Jan. 31, 2018	Jan. 31, 2017	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)
Advances on Inventory Purchases		$ 984,408				$ 984,408		$ 697,192
Additional Percentage of Director Compensation on Sales Value Using Certain Specify Technology	2.50%
Additional Percentage of Director Compensation Sales Value Using Other Kind of Technology	5.00%
Professional Fees						68,751
Consulting Services [Member]
Related Party Transaction, Expenses from Transactions with Related Party						50,000	$ 50,000
Innovest S.p.A. [Member] | Consulting Services [Member]
Related Party Transaction, Expenses from Transactions with Related Party						20,000	20,000
Former CEO [Member]
Employee Resignation Assertion, Gross Settlement			$ 175,000
Employee Resignation Assertion, Payment		80,555
Director of Clinical Affairs [Member]
Stock Issued During Period, Shares, Stock Options Exercised, Attributable to Consultants | shares	8,333
Royalty Expense						85,769	131,908
Professional Fees							$ 68,751
Instruments [Member]
Purchase Commitment Number Of Units					2,000
Purchase Commitment, Remaining Minimum Amount Committed		186,965				186,965
Devices [Member]
Purchase Commitment Number Of Units				2,000
Purchase Commitment, Remaining Minimum Amount Committed		$ 1,397,440				$ 1,397,440

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - Subsequent Event [Member]	May 14, 2018$ / sharesshares	Apr. 30, 2018USD ($)shares
Consulting Agreement [Member]
Contingent Consideration, Services, Option to Buy Shares | shares	500,000
Contingent Consideration, Services, Price Per Share | $ / shares	$ 1
Contingent Consideration, Services, Share Bought Threshold Trigger | shares	400,000
Contingent Consideration, Services, Additional Option to Buy Shares | shares	500,000
Contingent Consideration, Services, Ratio of Shares Bought to Additional Option, Numerator	4
Contingent Consideration, Services, Ratio of Shares Bought to Additional Option, Denominator	5
Consulting Agreement [Member] | Minimum [Member]
Contingent Consideration, Services, Share Bought Threshold Trigger Days	30 days
Consulting Agreement [Member] | Maximum [Member]
Contingent Consideration, Services, Share Bought Threshold Trigger Days	60 days
Milestone China [Member] | Sale of Variable Interest Entity's Shares [Member]
Return Obligation, Amount Repaid | $		$ 250,000
Termination Agreement, Number of Shares Returned | shares		1,400,000
Notes Receivable, Reversal Amount | $		$ 1,150,000
Equity Method Investment, Reversal of Deferred Gain on Sale | $		1,400,000
Termination Agreement, Gain (Loss) on Transaction | $		$ 0